Citations

Showing 10 of 108104 citations.

Knotless “Suture Staple” Technique for Endoscopic Partial Thickness Abductor Tendon Repair
Hartigan, David E. , Mansor, Yosif, Perets, Itay , Walsh, John P. , Mohr, Mitchell R., Domb, Benjamin G.

Mayo Clinic

Arthroscopy Techniques | September 1, 2018 | Volume: 7 | Issue: 10 | Pages: No page available

10.1016/j.eats.2018.06.002 | PMID 30666291 Get It

Abstract Transtendinous abductor tendon repair is a technique the authors described previously to diagnose and treat undersurface tears of the abductor tendons. In this surgical technique article, the authors describe a technique for knotless repair of undersurface tears of the abductor tendons that does not require a transtendinous split or suture passage through the abductor tendon. Because there is no suture passage through the abductor tendon or knot tying, the potential advantages include expeditious technique, compression of tendon against bony footprint, anatomic repair, and avoidance of knots facing the undersurface of the iliotibial band, which may lead to bursal irritation. Technique Video video See video under supplementary data.
ETHNIC DIFFERENCES IN POLYMORPHISMS OF TUMOR NECROSIS FACTOR-α, INTERLEUKIN-10, AND TRANSFORMING GROWTH FACTOR-β1 GENES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
Zein, Nizar N., Germer, Jeffrey J., El-Zayadi, Abdel Rahman, Vidigal, Pedro Guatimosim

Mayo Clinic

The American Journal of Tropical Medicine and Hygiene | September 1, 2018 | Volume: 70 | Issue: 4 | Pages: 434-437

10.4269/ajtmh.2004.70.434 Get It

Ethnic differences in the outcome of hepatitis C have been described. Our aim was to investigate ethnic differences in the distribution of genotypes associated with polymorphisms of the tumor necrosis factor-α promoter, interleukin-10 promoter, and transforming growth factor-β1 leader sequence in patients with hepatitis C. Genomic DNA was obtained from 71 Egyptians and 67 Caucasians (hepatitis C and control patients). Amplification of appropriate gene segments was followed by direct sequencing. Infrequently occurring polymorphisms were identified at positions −244 and −77 of the tumor necrosis factor-α promoter and at positions −851 and −657 of the interlukin-10 promoter. The G/A genotype associated with tumor necrosis factor-α promoter positions −376 and −244 was more frequent in Egyptians (P =0.001 and P =0.004, respectively). The −244 G/A genotype occurred only in healthy Egyptians (P =0.024). Thus, ethnic differences in the distribution of genotypes of the tumor necrosis factor-α promoter exist, which may have clinical implications on the outcome of hepatitis C.
EVALUATION OF A REAL-TIME POLYMERASE CHAIN REACTION ASSAY FOR THE DIAGNOSIS OF MALARIA IN PATIENTS FROM THAILAND
Swan, H., Sloan, Lynne M., Muyombwe, Anthony, Chavalitshewinkoon-Petmitr, Porntip , Krudsood, Srivicha, Leowattana, Wattana , Wilairatana, Polrat , LOOAREESUWAN, SORNCHAI, Rosenblatt, Jon E., SWAN, HEATHER

Mayo Clinic

The American Journal of Tropical Medicine and Hygiene | September 1, 2018 | Volume: 73 | Issue: 5 | Pages: 850-854

10.4269/ajtmh.2005.73.850 Get It

We compared the diagnosis of malaria in 297 patients from Thailand by a real-time polymerase chain reaction (PCR) assay using the LightCycler with conventional microscopy using Giemsa-stained thick and thin blood films. The PCR assay can be completed in one hour and has the potential to detect and identify four species of Plasmodium in a single reaction by use of melting temperature curve analysis (however, we did not detect Plasmodium ovale in this study). Blood was collected, stored, and transported on IsoCode STIX, which provide a stable matrix for the archiving and rapid simple extraction of DNA. A genus-specific primer set corresponding to the 18S ribosomal RNA was used to amplify the target sequence. Fluorescence resonance energy technology hybridization probes were designed for P. falciparum over a region containing basepair mismatches, which allowed differentiation of the other Plasmodium species. The PCR results correlated with the microscopic results in 282 (95%) of 297 patient specimens. Most of these were single-species infections caused by P. vivax (150) and P. falciparum (120), along with 5 P. malariae, 2 mixed infections (P. falciparum and P. vivax), and 5 negative specimens. No negative microscopy specimens were positive by PCR (100% specificity for detection of any Plasmodium). The 15 discrepant results could not be resolved, but given the subjective nature of microscopy and the analytical objectivity of the PCR, the PCR results may be correct. The ability of the PCR method to detect mixed infections or to detect P. ovale could not be determined in this study. Within the limitations of initial equipment costs, this real-time PCR assay is a rapid, accurate, and efficient method for the specific diagnosis of malaria. It may have application in clinical laboratories, as well as in epidemiologic studies and antimalarial efficacy trials.
Detection of Plasmodium knowlesi by Real-Time Polymerase Chain Reaction
Sloan, Lynne M., Rosenblatt, Jon E., Pritt, Bobbi S. , Pritt, Bobbi S , Babady, N. Esther

Mayo Clinic

The American Journal of Tropical Medicine and Hygiene | September 1, 2018 | Volume: 81 | Issue: 3 | Pages: 516-518

10.4269/ajtmh.2009.81.516 Get It

We previously developed a real-time polymerase chain reaction (PCR) assay for detection of the four Plasmodium species that infect humans. Recent studies have shown that natural transmission of the simian parasite Plasmodium knowlesi to humans occurs frequently in Southeast Asia. We have expanded our PCR assay to include detection of P. knowlesi.
Comparison of Chlorproguanil-Dapsone with a Combination of Sulfadoxine-Pyrimethamine and Chloroquine in Children with Malaria in Northcentral Nigeria
Ogunfowokan, Oluwagbenga , Madaki, Aboi J. K., Dankyau, Musa , Thacher, Tom D.

Mayo Clinic

The American Journal of Tropical Medicine and Hygiene | September 1, 2018 | Volume: 80 | Issue: 2 | Pages: 199-201

10.4269/ajtmh.2009.80.199 Get It

Effective and affordable treatment of malaria is critical in the face of resistance of Plasmodium falciparum to chloroquine (CQ) and sulfadoxine-pyrimethamine (SP). We conducted a randomized controlled trial comparing the efficacy of chlorproguanil-dapsone (CD) with a combination SP plus CQ in children in Nigeria less than five years of age with malaria. Of 264 children enrolled, 122 (89.7%) and 118 (92.2%) completed the study in the SP + CQ and CD groups, respectively. By day 3, 96 (78.7%) and 94 (79.7%) had cleared their parasitemia (P = 0.79), and 107 (87.7%) and 109 (92.4%) were symptom free (P = 0.32) in the SP + CQ and CD groups, respectively. Adequate clinical and parasitologic response at day 14 occurred in 111 (94.1%; 95% confidence interval [CI] = 91.6–95.7%) in the CD group and 113 (92.6%; 95% CI = 89.9–94.3%) in the SP + CQ group (P = 0.85). SP + CQ and CD had similar antimalarial efficacy and still provide affordable treatment of uncomplicated malaria in northcentral Nigeria.
COMPARISON OF SULFADOXINE-PYRIMETHAMINE WITH AND WITHOUT CHLOROQUINE FOR UNCOMPLICATED MALARIA IN NIGERIA
Pitmang, Simon, Madaki, J.K.A. , Egah, Daniel, Thacher, Tom D. , Fischer, Philip R.

Mayo Clinic

The American Journal of Tropical Medicine and Hygiene | September 1, 2018 | Volume: 72 | Issue: 3 | Pages: 263-266

10.4269/ajtmh.2005.72.263 Get It

While resistance to older antimalarials is increasingly common, newer antimalarials are still not widely available or affordable in much of Africa. Older antimalarials used in combination might be adequately effective in treating uncomplicated malaria. The objective of this study was to determine whether the combination of sulfadoxine-pyrimethamine (SP) and chloroquine (CQ) is superior to SP alone in the treatment of uncomplicated Plasmodium falciparum malaria in Nigerian patients. We recruited subjects with malaria, defined as the presence of fever and parasitemia > 2,000/μL, from the outpatient department of a Nigerian teaching hospital. We alternately assigned 280 subjects to receive SP with or without CQ. We assessed clinical and parasitologic responses on days 1, 2, 3, 7, and 14. A total of 114 in the SP + CQ group and 116 in the SP group completed the study. By day 3, 97 (75%) in the SP + CQ group and 52 (42%) in the SP group had cleared their parasitemia (P < 0.001); by day 14, 112 (98%) and 67 (58%), respectively, had cleared their parasitemia (P < 0.001). By day 3, 82 (63%) in the SP + CQ group and 20 (16%) in the SP group were symptom free (P < 0.001). When a modified World Health Organization clinical classification system was used, adequate clinical response occurred in 99 (87%) and 61 (53%) of those in the SP + CQ and SP groups, respectively. RI, RII, and RIII resistance to SP + CQ was 7.9%, 3.5%, and 1.8%, respectively, whereas resistance to SP was 23%, 17%, and 5%, respectively. Combined SP + CQ is superior to SP alone for treatment of uncomplicated malaria in Nigerian patients and may prolong the usefulness of these readily available and affordable drugs.
Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis
Moran, Sarah , Zgaga, Lina , Cuthbertson, David, Carette, Simon , Koening, Curry L. , Langford, Carol A. , McAlear, Carol A. , Moreland, Larry W. , Sreih, Antoine G. , Ytterberg, Steven R. , Little, Mark A. , Cuthbertson, David , Moreland, Larry W , Monach, Paul A. , Khalidi, Nader , Pagnoux, Christian , Seo, Philip , Specks, Ulrich , Wyse, Jason , Merkel, Peter A.

Mayo Clinic

Nephrology Dialysis Transplantation | September 1, 2018 | Volume: 35 | Issue: 2 | Pages: 283-291

10.1093/ndt/gfy300 | PMID 30380100 Get It

Abstract Background Prior work has shown that urinary soluble CD163 (usCD163) displays excellent biomarker characteristics for detection of active renal vasculitis using samples that included new diagnoses with highly active renal disease. This study focused on the use of usCD163 in the detection of the more clinically relevant state of mild renal flare and compared results of usCD163 testing directly to testing of urinary monocyte chemoattractant protein-1 (uMCP-1). Methods Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV, n = 88) were identified within a serially sampled, longitudinal and multicentre cohort. Creatinine-normalized usCD163 and uMCP-1 levels were measured by enzyme-linked immunosorbent assay and, both alone and in combination, were compared between times of active renal AAV and during remission and/or active non-renal AAV. Results Samples from 320 study visits included times of active renal vasculitis (n = 39), remission (n = 233) and active extrarenal vasculitis (n = 48). Median creatinine levels were 0.9 mg/dL [interquartile range (IQR) 0.8–1.2] in remission and 1.4 mg/dL (IQR 1.0–1.8) during renal flare. usCD163 levels were higher in patients with active renal vasculitis compared with patients in remission and those with active extrarenal vasculitis, with median values of 162 ng/mmol (IQR 79–337), 44 (17–104) and 38 (7–76), respectively (P &lt; 0.001). uMCP-1 levels were also higher in patients with active renal vasculitis compared with patients in remission and those with active extrarenal vasculitis, with median values of 10.6 pg/mmol (IQR 4.6–23.5), 4.1 (2.5–8.4) and 4.1 (1.9–6.8), respectively (P &lt; 0.001). The proposed diagnostic cut-points for usCD163 and uMCP-1 were 72.9 ng/mmol and 10.0 pg/mmol, respectively. usCD163 and uMCP-1 levels were marginally correlated (r2 = 0.11, P &lt; 0.001). Combining novel and existing biomarkers using recursive tree partitioning indicated that elevated usCD163 plus either elevated uMCP-1 or new/worse proteinuria improved the positive likelihood ratio (PLR) of active renal vasculitis to 19.2. Conclusion A combination of usCD163 and uMCP-1 measurements appears to be useful in identifying the diagnosis of subtle renal vasculitis flare.
The unfolding spectrum of inherited distal myopathies
Milone, Margherita , Liewluck, Teerin , Liewluck, T

Mayo Clinic

Muscle & Nerve | September 1, 2018 | Volume: 59 | Issue: 3 | Pages: 283-294

10.1002/mus.26332 | PMID 30171629 Get It

ABSTRACTDistal myopathies are a group of rare muscle diseases characterized by distal weakness at onset. Although acquired myopathies can occasionally present with distal weakness, the majority of distal myopathies have a genetic etiology. Their age of onset varies from early‐childhood to late‐adulthood while the predominant muscle weakness can affect calf, ankle dorsiflexor, or distal upper limb muscles. A spectrum of muscle pathological changes, varying from nonspecific myopathic changes to rimmed vacuoles to myofibrillar pathology to nuclei centralization, have been noted. Likewise, the underlying molecular defect is heterogeneous. In addition, there is emerging evidence that distal myopathies can result from defective proteins encoded by genes causative of neurogenic disorders, be manifestation of multisystem proteinopathies or the result of the altered interplay between different genes. In this review, we provide an overview on the clinical, electrophysiological, pathological, and molecular aspects of distal myopathies, focusing on the most recent developments in the field. Muscle Nerve 59:283–294, 2019
Reiki for Pain During Hemodialysis: A Feasibility and Instrument Evaluation Study
Zins, Savannah, Hooke, Mary Catherine, Gross, Cynthia R.

Mayo Clinic

Journal of Holistic Nursing | September 1, 2018 | Volume: 37 | Issue: 2 | Pages: 148-162

10.1177/0898010118797195 | PMID 30170509 Get It

Purpose: Pain is a problem for individuals undergoing hemodialysis. Renal disease, comorbidities, concurrent symptoms, and dialysis procedures pose barriers to adequate pain management. The purpose of this study was to evaluate feasibility, examine construct validity of The Patient-Reported Outcomes Measurement Information System (PROMIS) computerized adaptive testing (CAT) instruments, and explore pain benefits of Reiki sessions conducted during hemodialysis. Design: A one group, repeated-measures design was used. Method: Fifteen participants received Reiki for 20 minutes, twice a week for 4 weeks. Pain, fatigue, and depression were evaluated using established symptom scales and PROMIS CAT instruments. Findings: Participants reported general relaxation feelings with Reiki and acceptability of using a touch-screen device to respond to web-based measures. Although staff were initially reluctant to engage patients for Reiki, they reported Reiki did not interfere with workflow and thought Reiki could be integrated into the practice setting. Significant, strong correlations with established symptom scales support construct validity of PROMIS CAT instruments. There was a significant decrease in mean symptom scores after four weeks of Reiki. Effect size values suggest a range of practical significance. Conclusions: Findings suggest Reiki provides symptom relief for individuals receiving hemodialysis, and randomized clinical trials to establish Reiki’s pain benefits in this population are warranted.
Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease
Torres, Vicente E. , Torres, Vicente E

Mayo Clinic

Nephrology Dialysis Transplantation | September 1, 2018 | Volume: 34 | Issue: 1 | Pages: 30-34

10.1093/ndt/gfy297 | PMID 30312438 Get It

ABSTRACT No treatment until now has directly targeted the mechanisms responsible for the development and growth of cysts in autosomal dominant polycystic kidney disease (ADPKD). Strong rationale and preclinical studies using in vitro and in vivo models justified the launching of two large phase 3 clinical trials of tolvaptan in early and later stages of ADPKD. Their design was based on preliminary studies informing on the pharmacokinetics, pharmacodynamics, short-term safety and self-reported tolerability in patients with ADPKD. Tolvaptan slowed kidney growth in the early stage and estimated glomerular filtration rate decline in early and later stages of the disease. All participants had the opportunity to enroll in open-label extension trials to ascertain long-term safety and efficacy. In a single-center analysis of long-term outcomes, the effect of tolvaptan was sustained and cumulative over time supporting a disease-modifying effect of tolvaptan in ADPKD. In the countries where tolvaptan has been approved by regulatory agencies, patients with rapidly progressive ADPKD should be informed about the option of treatment including possible benefits and risks. If a decision to initiate treatment is made, prescribing physicians should educate the patients on the prevention of aquaresis-related adverse events and should be vigilant in the surveillance and management of the potential tolvaptan hepatotoxicity. Other vasopressin V2 receptor antagonists, possibly without potential hepatotoxicity, alternative strategies targeting vasopressin and combination with other drugs able to enhance the efficacy or reduce the aquaresis associated with tolvaptan, deserve further study.